Fig. 4.

Performance of predicted drugs in the bioprinted scar model. (A) The enrichment of gene sets from the GO database. (B) Schematic illustration of mechanism of drug screen. (C, D) The expression of pro-fibrotic molecule and anti-fibrotic molecule at gene (C) (Data are mean ± SEM, n = 3, *p < 0.05) and protein (D) level (α-SMA, TGFβ1, TGFβ3: green, DAPI: blue, scale bar = 25 μm). 3ASS: 3A5G+SFb+scar ECM, 3A–D: 3ASS+DMSO, 3A–A: 3ASS+ Abemaciclib, 3A–C: 3ASS+ Cobimetinib, 3A–T: 3ASS+ Triamcinolone acetonide. (For interpretation of the references to colour in this figure legend, the reader is referred to the Web version of this article.)